Lumos Diagnostics Secures Follow-On Contract to Manage Study to Advance In-Home Phenylketonuria Monitoring Device to Support US FDA Clearance

MT Newswires Live

01/19

Lumos Diagnostics Holdings (ASX:LDX) secured a follow-on contract with Aptatek Biosciences to manage the institutional review board-approved multi-center study to advance an in-home monitoring tool for the screening and management of phenylketonuria to support clearance from the US Food and Drug Administration, according to a Monday Australian bourse filing.

Lumos will provide clinical study support services, from startup through to close-out, including compilation and statistical analysis of the results and generation of the clinical study report for submission to the US FDA. The study is expected to start in the second quarter and run for around six months.

This new contract is valued at around $400,000, which will be charged on a time-and-materials basis.

The firm's shares rose 2% in recent trading on Monday.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2604903283"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2604903283\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2604903283?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-19 09:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2604903283","market":"fut","top_or_hot":-1,"title":"Lumos Diagnostics Secures Follow-On Contract to Manage Study to Advance In-Home Phenylketonuria Monitoring Device to Support US FDA Clearance","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/LDXHF\">Lumos Diagnostics</a> Holdings (ASX:LDX) secured a follow-on contract with Aptatek Biosciences to manage the institutional review board-approved multi-center study to advance an in-home monitoring tool for the screening and management of phenylketonuria to support clearance from the US Food and Drug Administration, according to a Monday Australian bourse filing.</p><p>Lumos will provide clinical study support services, from startup through to close-out, including compilation and statistical analysis of the results and generation of the clinical study report for submission to the US FDA. The study is expected to start in the second quarter and run for around six months.</p><p>This new contract is valued at around $400,000, which will be charged on a time-and-materials basis.</p><p>The firm's shares rose 2% in recent trading on Monday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lumos Diagnostics Secures Follow-On Contract to Manage Study to Advance In-Home Phenylketonuria Monitoring Device to Support US FDA Clearance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLumos Diagnostics Secures Follow-On Contract to Manage Study to Advance In-Home Phenylketonuria Monitoring Device to Support US FDA Clearance\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-01-19 09:10</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/LDXHF\">Lumos Diagnostics</a> Holdings (ASX:LDX) secured a follow-on contract with Aptatek Biosciences to manage the institutional review board-approved multi-center study to advance an in-home monitoring tool for the screening and management of phenylketonuria to support clearance from the US Food and Drug Administration, according to a Monday Australian bourse filing.</p><p>Lumos will provide clinical study support services, from startup through to close-out, including compilation and statistical analysis of the results and generation of the clinical study report for submission to the US FDA. The study is expected to start in the second quarter and run for around six months.</p><p>This new contract is valued at around $400,000, which will be charged on a time-and-materials basis.</p><p>The firm's shares rose 2% in recent trading on Monday.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HBCP","symbol_name":"Home Bancorp Inc","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2604903283","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2604903283","pubTimestamp":1768785015,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Lumos Diagnostics Holdings  secured a follow-on contract with Aptatek Biosciences to manage the institutional review board-approved multi-center study to advance an in-home monitoring tool for the screening and management of phenylketonuria to support clearance from the US Food and Drug Administration, according to a Monday Australian bourse filing.Lumos will provide clinical study support services, from startup through to close-out, including compilation and statistical analysis of the results and generation of the clinical study report for submission to the US FDA. The study is expected to start in the second quarter and run for around six months.This new contract is valued at around $400,000, which will be charged on a time-and-materials basis.The firm's shares rose 2% in recent trading on Monday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HBCP":"Home Bancorp Inc","BK7126":"医疗保健用品","BK4195":"互助储蓄与抵押信贷金融服务","LDX.AU":"LUMOS DIAGNOSTICS HOLDINGS L","BK4211":"区域性银行"},"translate_title":"Lumos Diagnostics获得后续合同，管理改进家用苯丙酮尿症监测设备的研究，以支持美国FDA的批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LDX.AU":1,"HBCP":1.5},"content_text":"Lumos Diagnostics Holdings (ASX:LDX) secured a follow-on contract with Aptatek Biosciences to manage the institutional review board-approved multi-center study to advance an in-home monitoring tool for the screening and management of phenylketonuria to support clearance from the US Food and Drug Administration, according to a Monday Australian bourse filing.Lumos will provide clinical study support services, from startup through to close-out, including compilation and statistical analysis of the results and generation of the clinical study report for submission to the US FDA. The study is expected to start in the second quarter and run for around six months.This new contract is valued at around $400,000, which will be charged on a time-and-materials basis.The firm's shares rose 2% in recent trading on Monday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}